Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/28—Phosphorus compounds with one or more P—C bonds
  • C07F9/50—Organo-phosphines
  • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
  • C07F9/5325—Aromatic phosphine oxides or thioxides (P-C aromatic linkage)

Definitions

• This invention relates to vitamin D compounds, and more particularly to l-Desoxy-2-Methylene-19-Nor-Vitamin D analogs and their pharmaceutical uses, and especially (20S)-25-hydroxy-l-desoxy-2-methylene-19-norvitamin D 3 , its biological activities, and its pharmaceutical uses.
• the natural hormone, la,25-dihydroxyvitamin D3 and its analog in the ergosterol series, i.e. la,25-dihydroxyvitamin D2 are known to be highly potent regulators of calcium homeostasis in animals and humans, and their activity in cellular differentiation has also been established, Ostrem et al., Proc. Natl. Acad. Sci. USA, 84, 2610 (1987). Many structural analogs of these metabolites have been prepared and tested, including l -hydroxyvitamin D3, 1 a-hydroxyvitamin D2, various side chain homologated vitamins and fluorinated analogs. Some of these compounds exhibit an interesting separation of activities in cell differentiation and calcium regulation. This difference in activity may be useful in the treatment of a variety of diseases such as renal osteodystrophy, vitamin D-resistant rickets, osteoporosis, psoriasis, and certain malignancies.
• diseases such as renal osteodystrophy, vitamin D-resistant rickets, osteop
• vitamin D analogs i.e. the so called 19-nor-vitamin D compounds
• 19-nor-vitamin D compounds is characterized by the replacement of the A-ring exocyclic methylene group (carbon 19), typical of the vitamin D system, by two hydrogen atoms.
• the present invention is aimed at vitamin D compounds characterized by the transposition of the A-ring exocyclic methylene group from carbon 10 (C-10) to carbon 2 (C-2) (e.g., 2-methylene- 19-norvitamin D analogs). Although these analogs lack la-OH, that is important for biological activity, such hydroxyl group can be potentially introduced enzymatically in the living organisms.
• the present invention is directed toward l-desoxy-2-methylene- 19-nor- vitamin D analogs, and their pharmaceutical uses, and more specifically toward (20S)- 25-hydroxy-l-desoxy-2-methylene-1 -norvitamin D 3 , its biological activity, and various pharmaceutical uses for this compound.
• R represents any of the typical side chains known for vitamin D type compounds.
• n independently, represent the integers from 0 to 5, where R 1 is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C 1-5 -alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or
• side chains with natural 20R- configuration are the structures represented by formulas (a), (b), (c), (d) and (e) below, i.e., the side chain as it occurs in 25-hydroxyvitamin D 3 (a); vitamin D 3 (b); 25-hydroxyvitamin D 2 (c); vitamin D 2 (d); and the C-24 epimer of 25-hydroxyvitamin D 2 (e).
• carbon 20 may have either the R or S configuration.
• the preferred analog is (20S)-25-hydroxy- 1 -desoxy-2-methylene- 19- norvitamin D 3 which has the following formula la:
• These compounds are characterized by relatively high binding to vitamin D receptors, i.e. they bind with only slightly lower affinity than la,25-dihydroxyvitamin D3 They are only slightly less potent causing differentiation of HL-60 cells than l,25(OH) 2 D 3 . They also exhibit relatively low transcriptional activity as well as relatively low activity in their ability to mobilize calcium from bone, and in their ability to promote intestinal calcium transport, as compared to la,25-dihydroxyvitamin D 3 . Hence, these compounds can be characterized as having relatively little calcemic activity.
• the above compounds I, and particularly la have relatively high binding affinity, are characterized by relatively high cell differentiation activity, but have notably lower calcemic activities.
• these compounds have potential as anticancer agents and provide therapeutic agents for the prevention or treatment of leukemia, colon cancer, breast cancer, skin cancer and prostate cancer.
• One or more of the compounds may be present in a composition to treat or prevent the above-noted diseases in an amount from about 0.0 ⁇ g/gm to about 1000 g gm of the composition, preferably from about 0. ⁇ g/gm to about 500 ⁇ of the composition, and may be administered topically, transdermally, orally, rectally, nasally, sublingually, or parenterally in dosages of from about 0.0 ⁇ g/day to about 1000 ⁇ g/day, preferably from about O. ⁇ g/day to about 500 ⁇ g/day.
• Figures 1-5 illustrate various biological activities of (20S)-25-hydroxy- l-desoxy-2-methylene-19-norvitamin D 3 , hereinafter referred to as "l-desoxy-2MD,” as compared to the native hormone la,25-dihydroxyvitamin D 3 , hereinafter
• Figure 1 is a graph illustrating the relative activity of l-desoxy-2MD and l,25(OH) 2 D 3 to compete for binding with [ 3 H]-l,25-(OH) 2 -D 3 to the full-length recombinant rat vitamin D receptor;
• Figure 2 is a graph illustrating the percent HL-60 cell differentiation as a function of the concentration of l-desoxy-2MD and l,25(OH) 2 D 3 ;
• Figure 3 is a graph illustrating the in vitro transcription activity of l,25(OH) 2 D 3 as compared to l-desoxy-2MD;
• Figures 4A and 4B are bar graphs illustrating the bone calcium mobilization activity of l,25(OH) 2 D 3 as compared to l-desoxy-2MD;
• Figures 5 A and 5B are bar graphs illustrating the intestinal calcium transport activity of l,25(OH) 2 D 3 as compared to l-desoxy-2MD.
• hydroxy- protecting group signifies any group commonly used for the temporary protection of hydroxy functions, such as for example, alkoxycarbonyl, acyl, alkylsilyl or
• alkylarylsilyl groups (hereinafter referred to simply as "silyl” groups), and alkoxyalkyl groups.
• Alkoxycarbonyl protecting groups are alkyl-O-CO- groupings such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl,
• acyl signifies an alkanoyl group of 1 to 6 carbons, in all of its isomeric forms, or a carboxyalkanoyl group of 1 to 6 carbons, such as an oxalyl, malonyl, succinyl, glutaryl group, or an aromatic acyl group such as benzoyl, or a halo, nitro or alkyl substituted benzoyl group.
• alkyl denotes a straight-chain or branched alkyl radical of 1 to 10 carbons, in all its isomeric forms.
• Alkoxy refers to any alkyl radical which is attached by oxygen, i.e. a group represented by "alkyl-O-.”
• Alkoxyalkyl protecting groups are groupings such as methoxymethyl, ethoxymethyl, methoxyethoxymethyl, or tetrahydrofuranyl and tetrahydropyranyl.
• Preferred silyl-protecting groups are trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, dibutylmethylsilyl,
• a "protected hydroxy” group is a hydroxy group derivatised or protected by any of the above groups commonly used for the temporary or permanent protection of hydroxy functions, e.g. the silyl, alkoxyalkyl, acyl or alkoxycarbonyl groups, as previously defined.
• hydroxyalkyl refers to an alkyl radical substituted by one or more hydroxy, deuterium or fluoro groups respectively.
• An “alkylidene” refers to a radical having the general formula C k H 2k - where k is an integer.
• groups X and R represent groups defined above; X being preferably hydroxy-protecting group, it being also understood that any functionalities in R that might be sensitive, or that interfere with the condensation reaction, be suitable protected as is well-known in the art.
• the process shown above represents an application of the convergent synthesis concept, which has been applied effectively for the preparation of vitamin D compounds [e.g. Lythgoe et al., J. Chem. Soc. Perkin Trans. I, 590 (1978); Lythgoe, Chem. Soc. Rev. 9, 449 (1983); Toh et al., J. Org. Chem. 48, 1414 (1983); Baggiolini et al., J. Org. Chem.
• Hydrindanones of the general structure II are known, or can be prepared by known methods. Specific important examples of such known bicyclic ketones are the structures with the side chains (a), (b), (c) and (d) described above, i.e., 25- hydroxy Grundmann's ketone (e) [Baggiolini et al., J. Org.
• the introduced secondary hydroxyl was silylated and the protected compound 3 was subjected to the Wittig reaction with an ylide generated from methyltriphenylphosphonium bromide and z-butyllithium.
• the carbonyl group was deprotected in the reaction with the Lewis acid (FeCl 3 ) and the formed cyclohexanone 5 was subjected to a Peterson reaction leading to the mixture of ⁇ , ⁇ -unsaturated esters 6 and 7.
• the separation of the geometric isomers was more easily achieved (by column chromatography) after the reduction step, providing the E- and Z-allylic alcohols 8 and 9, respectively.
• the E-isomer 8 was next transformed in the three-step procedure into the corresponding phosphine oxide 10.
• Wittig-Horner coupling of the known Grundmann ketone 11 [see Sicinski et al., J. Med. Chem., 41, 4662 (1998)] with the lithium phosphinoxy carbanion generated from the phosphine oxide 10 was subsequently carried out, producing the protected 19-norvitamin D compound, which after hydroxyls deprotection with tetrabutylammonium fluoride provided the desired (205)-2-methylene-25-hydroxy-19-nor- vitamin D 3 (12, 1-desoxy- 2MD).
• This synthetic path is described in EXAMPLE I herein and the alternative method of the synthesis of the A-ring fragment, the phoshine oxide 27, and its coupling with the ketone 11 is described in EXAMPLE II herein.
• SCHEME II shows this different synthetic sequence leading to the building block 27 and to the final vitamin 12.
• a chiral starting compound served a commercially available D-(-)-quinic acid 13, which was at first converted to the known lactone 14.
• Treatment of this compound with a 1, 1 '-thiocarbonyldiimidazole resulted in formation of the cyclic thiocarbonate 15 [see Mills et al., Tetrahedron Lett. 29, 281 (1988)].
• the Barton-McCombie deoxygenation reaction of the thiocarbonate 15 with tributyltin hydride and AIBN provided two isomeric products: the known compound 16 [see Gonzales-Bello et al., J. Chem.
• the E-isomer 25 was then converted into the corresponding allylic phosphine oxide 27. Its anion, generated by phenyllitium, was coupled with the Grundmann ketone 11 and the final 19-norvitamin 12 (l-desoxy-2MD) was obtained after acidic hydroxyl deprotection.
• Butyldiphenylsilyl)oxy]-4-methylene-cyclohexanone (5) To a solution of ketal 4 (160 mg, 0.392 mmol) in methylene chloride (11 mL) at room temperature FeCl 3 ⁇ 6H 2 0 (547 mg, 2.02 mmol) was added. The resulting dark yellow suspension was stirred for 50 min and quenched by the addition of water. The aqueous layer was extracted with methylene chloride, the combined organic layers were dried (MgS0 4 ) and
• keto compound 5 (63 mg, 172.8 umol) in anhydrous THF (300 uL + 80 ⁇ ) was added dropwise. The solution was stirred at -78 °C for 2 hours, and the reaction was quenched with saturated H 4 C1, poured into brine and extracted with ethyl acetate. The combined organic extracts were dried (MgS0 4 ) and evaporated. The residue was dissolved in hexane and applied on a silica Sep-Pak cartridge. Elution with hexane/ethyl acetate (98:2) gave unsaturated esters 6 and 7 (65 mg, 90%) as a colorless oil.
• Diisobutylaluminium hydride (1.5 M in toluene; 1.9 mL, 2.85 mmol) was slowly added to a stirred solution of allylic esters 6 and 7 (165 mg, 0.392 mmol) in toluene '.methylene chloride (2:1; 8 mL) at -78 °C under argon. Stirring was continued at -78 °C for 1 h and at -40 °C for 30 min. The mixture was quenched by slow addition of potassium-sodium tartate (2N, 4 mL), aqueous HC1 (2N, 4 mL) and H 2 0 (14 mL), and extracted with ethyl acetate.
• Butyldiphenylsilyl)oxy]-4'-methylene-cyclohexylidene]ethyI]diphenyl phosphine oxide (10).
• a solution of a freshly recrystallized tosyl chloride (24 mg, 125 ⁇ ) in anhydrous THF (230 ⁇ ,) was then added to the allylic alcohol - w-BuLi solution.
• n-BuLi 2.5 M in hexanes; 12 ⁇ , 29.7 umol
• the solution turned red.
• the mixture was cooled to -78 °C, and precooled (- 78 °C) solution of protected hydroxy ketone 11 (3 mg, 7.62 ⁇ ) in anhydrous THF (60 L + 40 ⁇ ,) was slowly added.
• the mixture was stirred under argon at -78 °C for
• Ketolactone 18 (0.38 g, 2.43 mmol) in THF (10 mL) was added via cannula and stirring was continued at room temperature for next 2 h. The solvent was then removed under reduced pressure and the residue was partitioned between ethyl acetate (20 mL) and brine (40 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (5 x 20 mL). The organic extracts were combined, dried (MgS0 ), filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica (30% ethyl acetate/hexane) to give the semisolid compound 19 (0.30 g, 80%).
• the crude methyl ester was dissolved in anhydrous methylene chloride (30 mL) and 2,6-lutidine (1.26 mL;1.16 g, 10.84 mmol), cooled to -40 °C and tert-butyldimethylsilyl trifluoromethanesulfonate (1.97 mL; 2.26 g, 8.56 mmol) was added dropwise.
• the reaction mixture was stirred at -40 °C for 50 min.
• Wet methylene chloride (10 mL) was added slowly, cooling bath was removed and the reaction mixture was allowed to warm up slowly to room temperature.
• Butyldimethylsilyl)oxy]-4'-methylene-cyclohexylidene]acetic acid methyl ester (mixture of 23 and 24).
• ketone 22 (0.65 g, 2.38 mmol) in anhydrous benzene (20 mL) methyl(triphenylphosphoranylidene) acetate (1.59 g, 4.77 mmol) was added.
• the reaction mixture was heated under reflux for 15 h, then concentrated under reduced pressure and the residue was purified on a silica Sep-Pak cartridge (3 ⁇ 5% ethyl acetate/hexane) to afford a mixture of unsaturated esters 23 and 24
• Butyldimethylsilyl)oxy]-4'-methylenecyclohexylidene]ethyl]diphenylphosphine Oxide (27).
• a allylic alcohol 25 (190.0 mg, 708 umol) in anhydrous THF (5 mL) was added «-BuLi (1.6 M in hexanes; 450 uL, 125 ⁇ mol) under argon at 0 °C.
• a solution of a freshly recrystallized tosyl chloride (141.5 mg, 743 ⁇ ) in anhydrous THF (1.5 mL) was then added to the allylic alcohol - «-BuLi solution.
• compound l-desoxy-2MD is a highly selective analog with unique biological activity.
• Figures 5 A and 5B show that l-desoxy-2MD has relatively low activity as compared to that of 1,25-dihydroxyvitamin D 3 (l,25(OH) 2 D ), the natural hormone, in stimulating intestinal calcium transport.
• l-desoxy-2MD is about 20 times less potent than l,25(OH) 2 D 3 in promoting active calcium transport across the gut.
• Figures 4A and 4B demonstrate that l-desoxy-2MD has relatively low bone calcium mobilization activity, as compared to l,25(OH) 2 D .
• l-desoxy-2MD is less potent than the native hormone in releasing bone calcium stores as little to no activity is observed until 7020 pmol/rat is administered; whereas, significant increases in serum calcium are observed at 780 pmol when the native hormone is given.
• Figures 4-5 thus illustrate that l-desoxy-2MD may be characterized as having relatively low calcemic activity.
• Figure 2 illustrates that l-desoxy-2MD is almost as potent as
• Figure 3 illustrates that the compound l-desoxy-2MD has less transcriptional activity than la,25-dihydroxyvitamin D 3 in bone cells. In bone cells, 1 -desoxy-2MD is about 20 times less potent than l,25(OH) 2 D 3 in increasing transcription of the 24-hydroxylase gene. This result, together with the cell differentiation activity of Figure 2, suggests that l-desoxy-2MD will be very effective in treating the above referred to cancers because it has direct cellular activity in causing cell differentiation, gene transcription, and in suppressing cell growth.
• Radiolabeled and unlabeled ligands were added to 100 mcl of the diluted protein at a final ethanol concentration of ⁇ 10%, mixed and incubated overnight on ice to reach binding equilibrium. The following day, 100 mcl of hydroxy lapatite slurry (50%) was added to each tube and mixed at 10-minute intervals for 30 minutes. The hydroxylapaptite was collected by centrifugation and then washed three times with Tris-EDTA buffer (50 mM Tris, 1.5 n M EDTA, pH 7.4) containing 0.5% Titron X- 100.
• Tris-EDTA buffer 50 mM Tris, 1.5 n M EDTA, pH 7.4
• the pellets were transferred to scintillation vials containing 4 ml of Biosafe II scintillation cocktail, mixed and placed in a scintillation counter. Total binding was determined from the tubes containing only radiolabeled ligand.
• HL60 cells were plated at 1.2 x 10 5 cells/ml. Eighteen hours after plating, cells in duplicate were treated with drug. Four days later, the cells were harvested and a nitro blue tetrazolium reduction assay was performed (Collins et al., 1979; J. Exp. Med. 149:969-974). The percentage of differentiated cells was determined by counting a total of 200 cells and recording the number that contained intracellular black-blue formazan deposits. Verification of differentiation to monocytic cells was determined by measuring phagocytic activity (data not shown).
• 1- desoxy-2MD has slightly less activity than the natural hormone la,25- dihydroxyvitamin D 3 in its ability to compete with [ 3 H]-l,25(OH) 2 D 3 for binding to the full-length recombinant rat vitamin D receptor ( Figure 1).
• l-desoxy-2MD will have significant activity as an anti-cancer agent, especially for preventing or treating leukemia, colon cancer, breast cancer, skin cancer and prostate cancer because it has direct cellular activity in causing cell differentiation and in suppressing cell growth.
• l-desoxy-2MD is an excellent candidate for numerous human therapies as described herein.
• l-desoxy-2MD is an excellent candidate for treating a cancer because: (1) it has significant VDR binding, transcription activity and cellular differentiation activity; (2) it has low risk of hypercalcemic liability unlike l,25(OH) 2 D 3 ; and (3) it is easily synthesized.
• the compounds of this invention defined by formula I and la may be formulated for pharmaceutical applications as a solution in innocuous solvents, or as an emulsion, suspension or dispersion in suitable solvents or carriers, or as pills, tablets or capsules, together with solid carriers, according to conventional methods known in the art. Any such formulations may also contain other pharmaceutically-acceptable and non-toxic excipients such as stabilizers, anti-oxidants, binders, coloring agents or emulsifying or taste-modifying agents.
• the compounds of formula I and particularly l-desoxy-2MD of formula la may be administered orally, topically, parenterally, rectally, nasally, sublingually, or transdermally.
• the compound is advantageously administered by injection or by intravenous infusion or suitable sterile solutions, or in the form of liquid or solid doses via the alimentary canal, or in the form of creams, ointments, patches, or similar vehicles suitable for transdermal applications.
• a dose of from 0.0 ⁇ g to 1000 ⁇ g per day of the compounds I, particularly l-desoxy-2MD, preferably from about O. ⁇ g to about 500 ⁇ g per day, is appropriate for prevention and/or treatment purposes, such dose being adjusted according to the disease to be treated, its severity and the response of the subject as is well understood in the art. Since the compound exhibits specificity of action, each may be suitably administered alone, or together with graded doses of another active vitamin D compound— e.g. l -hydroxyvitamin D2 or D3, or la,25- dihydroxyvitamin D3 ⁇ in situations where different degrees of bone mineral mobilization and calcium transport stimulation is found to be advantageous.
• another active vitamin D compound e.g. l -hydroxyvitamin D2 or D3, or la,25- dihydroxyvitamin D3 ⁇ in situations where different degrees of bone mineral mobilization and calcium transport stimulation is found to be advantageous.
• compositions for use in the above-mentioned treatments comprise an effective amount of the compounds I, particularly l-desoxy-2MD, as defined by the above formula I and la as the active ingredient, and a suitable carrier.
• An effective amount of such compound for use in accordance with this invention is from about 0.01 ⁇ g to about 1000 ⁇ g per gm of composition, preferably from about 0.1 g to about 500 ⁇ g per gram of composition, and may be administered topically, transdermally, orally, rectally, nasally, sublingually or parenterally in dosages of from about 0.0 ⁇ g/day to about 1000 ⁇ g /day, and preferably from about 0.1 ⁇ g/day to about 500 ⁇ g/day.
• the compounds I may be formulated as creams, lotions, ointments, topical patches, pills, capsules or tablets, suppositories, aerosols, or in liquid form as solutions, emulsions, dispersions, or suspensions in pharmaceutically innocuous and acceptable solvent or oils, and such preparations may contain in addition other pharmaceutically innocuous or beneficial components, such as stabilizers, antioxidants, emulsifiers, coloring agents, binders or taste-modifying agents.
• the compounds I may be advantageously administered in amounts sufficient to effect the differentiation of promyelocytes to normal macrophages. Dosages as described above are suitable, it being understood that the amounts given are to be adjusted in accordance with the severity of the disease, and the condition and response of the subject as is well understood in the art.
• the formulations of the present invention comprise an active ingredient in association with a pharmaceutically acceptable carrier therefore and optionally other therapeutic ingredients.
• the carrier must be "acceptable” in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient thereof.
• Formulations of the present invention suitable for oral administration may be in the form of discrete units as capsules, sachets, tablets or lozenges, each containing a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or nonaqueous liquid; or in the form of an oil-in-water emulsion or a water-in-oil emulsion.
• Formulations for rectal administration may be in the form of a suppository incorporating the active ingredient and carrier such as cocoa butter, or in the form of an enema.
• Formulations suitable for parenteral administration conveniently comprise a sterile oily or aqueous preparation of the active ingredient which is preferably isotonic with the blood of the recipient.
• Formulations suitable for topical administration include liquid or semi- liquid preparations such as liniments, lotions, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops; or as sprays.
• a nebulizer or an atomizer can be used for nasal administration, inhalation of powder, self-propelling or spray formulations.
• the formulations when dispensed, preferably have a particle size in the range of 10 to 100 ⁇ .
• the formulations may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy.
• dosage unit is meant a unitary, i.e. a single dose which is capable of being administered to a patient as a physically and chemically stable unit dose comprising either the active ingredient as such or a mixture of it with solid or liquid

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• General Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Physical Education & Sports Medicine (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Rheumatology (AREA)
• Oncology (AREA)
• Hematology (AREA)
• Dermatology (AREA)
• Urology & Nephrology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (2)

Family

ID=43823661

Family Applications (1)

Country Status (8)

Cited By (1)

Families Citing this family (1)

Citations (9)

Family Cites Families (13)

• 2010
  • 2010-09-30 EP EP10763286.1A patent/EP2483240B1/en not_active Not-in-force
  • 2010-09-30 MX MX2012003882A patent/MX2012003882A/es active IP Right Grant
  • 2010-09-30 NZ NZ599216A patent/NZ599216A/en not_active IP Right Cessation
  • 2010-09-30 CA CA2776464A patent/CA2776464C/en not_active Expired - Fee Related
  • 2010-09-30 WO PCT/US2010/050977 patent/WO2011041590A2/en not_active Ceased
  • 2010-09-30 JP JP2012532328A patent/JP5814247B2/ja not_active Expired - Fee Related
  • 2010-09-30 US US12/895,478 patent/US8642579B2/en active Active
  • 2010-09-30 AU AU2010300539A patent/AU2010300539B9/en not_active Ceased

Patent Citations (10)

Non-Patent Citations (24)

Also Published As

Similar Documents

Legal Events